Recent Web and print articles
- Science and Enterprise. Another Chance to
Get Serious on Drug Pricing. 27 May 2016. A Science magazine commentary proposed a model for calculating the economic
value for new gene therapies, one day after the president of the pharmaceutical industry assoiation in the U.S. said it
would consider pragmatic ideas for value-based drug purchasing. Science & Enterprise says this proposal offers the
pharma industry an opportunity to show it is serious about solving this problem.
- Science and Enterprise. Drug Pricing Reform
Even Big Pharma Might Like. 2 May 2016. In a special report, Science & Enterprise proposes the pharmaceutical
industry collaborate with other players in the health care industry to bring down the high cost of drug development, with
savings passed on to the customers. The industry now faces a more hostile political environment and competition from new
- LinkVehicle.com. A Blog You Can Trust. 4 January 2016. The success of your blog isn't only about your content. It's
as much about your readers and the relationship you build with them. Also published on Medium and LinkedIn.
- Science and Enterprise. The Next Health
Care Disruption. 29 September 2015. The pharmaceutical industry must reform its business practices to bring down
costs of prescription drugs. If the industry doesn't change from within, others will do it for them, and it won't
be pretty. Part of the special Think Further series,
sponsored by investment company Fred Alger Management.
- LinkedIn. Making Bootstraps: A Mid-Career Break to Boost Wage Growth. 15 March 2015. Universal Sabbatical for
Advancement grants would be modeled after the G.I. Bill and provide workers with a mid-career break for a year to build
skills for higher-paying jobs. Also posted on
Science and Technology.
Job Loyalty Revisited: Earned, not Entitled. 7 September 2014. Employers face the challenge of creating an
environment where job security and career advancement are more the norm than the exception. Career advancement is
something managers at all levels can provide, and often without incurring much expense.
- LinkedIn. Job Loyalty Revisited: Lessons from Market Basket. 1 September 2014. For American workers, the Market
Basket story should raise a few questions about loyalty owed to an employer, and restoring some of the balance that seems
weighted way in favor of the people signing pay checks.
- Seeking Alpha. Sanofi Bolsters Vaccine Business. 18 August 2014. Sanofi Pasteur, the pharmaceutical company's vaccines
division, has important new releases coming up in late-stage clinical trials and for regulatory review.
- Seeking Alpha. Shire Acquisition Bolsters Its Rare, And Maybe Not-So-Rare, Disease Portfolio. 19 May 2014. The
acquisition by Shire plc earlier this month of Lumena Pharmaceuticals builds Shire's already strong position in rare
diseases, but the acquisition can also help Shire advance drug development programs aimed at larger populations.
My Mission: Journalists Who Love Math. 26 April 2014. For too many reporters of all kinds, covering a story with
any amount of quantification seems to make them surrender to the words in a press release. I'm on a mission to
- Seeking Alpha. New GlaxoSmithKline Diabetes Drug Needs Innovative Marketing Strategy. 21 April 2014. A diabetes drug
approved last week for sale in the U.S. and Europe brings GlaxoSmithKline (GSK) into a new therapy field for the company,
one that is both crowded and changing rapidly with the ageing of baby boomers and new directions in health care.
- Seeking Alpha. Myriad Genetics' Acquisition Of Crescendo Bioscience: A Question Of Timing. 10 February 2014.
"At first glance, the acquisition makes a lot of sense for Myriad, adding a ready-made capability in a
complementary line, but also this week, the scientific landscape changed markedly for rheumatoid arthritis and similar
disorders, adding a wrinkle into Myriad's plans for the company."
More articles, by year:
2013 | 2009-12 | 2008 |
2007 | 2006 |
2005 | 2004 |
2003 | 2002
2000-2001 | 1990-1999 | -1989